No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9.
Irbesartaani manustamisel koos varfariiniga, ravimiga, mis metaboliseerub CYP2C9 kaudu ei ilmnenud märkimisväärseid farmakokineetilisi ega farmakodünaamilisi koostoimeid.